An investigation into bribery is one of the issues facing Swiss pharmaceutical company Novartis
Keystone
Swiss pharmaceutical giant Novartis is under investigation in South Korea, a spokeswoman for the company told swissinfo.ch on Monday via email.
This content was published on
1 minute
swissinfo.ch
“We can confirm that the headquarters of Novartis Korea in Seoul were visited by local authorities in relation to an investigation on Feb 22, 2016,” she wrote.
According to media reports, Novartis is suspected of offering bribes to local doctors in the form of rebates for products.
The spokeswoman from the Novartis Media Relations department said that Novartis “is committed to high standards of ethical business conduct and regulatory compliance in all aspects of our work and we take any allegation of misconduct extremely seriously.”
The company is “cooperating fully with the authorities and will continue to support the investigation as requested,” she wrote. “We cannot comment further on this ongoing investigation.”
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Big pharma’s business model under the microscope
This content was published on
In recent days, Johnson & Johnson has been urged to review its sprawling portfolio that ranges from baby oil to cancer drugs, and there were questions for Novartis over the future of its struggling eyecare business. This week, Pfizer will update shareholders on plans for a potential break-up, while GlaxoSmithKline is likely to be pressed…
Novartis offers cheap drugs for developing countries
This content was published on
Baptised “Novartis Access” the affordable drugs portfolio is targeted at chronic diseases like diabetes, respiratory illnesses, cardiovascular diseases and breast cancer. The choice was made based on the World Health Organization’s (WHO) Essential Medicines List and the drugs are also the most prescribed medicines in the 30 countries that will benefit from the reduced rates. …
This content was published on
“Personally, I have welcomed the wages that I have received,” a broadly smiling Vasella told Swiss television at the end of January after announcing his intention to stand down as chairman of the pharmaceuticals giant on February 22. Vasella stayed true to his word, accepting a so-called “non-compete” pay-out of up to CHF72 million ($78…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.